Development and optimization of nanosomal formulations for siRNA delivery to the liver - Wikidata - wikimedia - TriplyDB

Development and optimization of nanosomal formulations for siRNA delivery to the liver

Development and optimization of nanosomal formulations for siRNA delivery to the liver

http://www.wikidata.org/entity/Q35816825

about

Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery.Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer.Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy.Novel nanosomes for gene delivery to Plasmodium falciparum-infected red blood cells Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.Targeting Splicing in the Treatment of Human Disease Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication.

P2860

Q26859021-8AB95159-4ED3-4C99-AC64-CA362FCDB77C Q33613510-AF0405EF-3221-45E6-A174-A957C496AEE5 Q36195057-4ECB53D6-E590-4C38-93D6-C5880ECDB9A5 Q36220684-35CBDE79-35AF-40C2-A1D3-E22FE4642FF8 Q36411432-B44555FB-D04C-4B80-BC68-74F8D68D3604 Q36916437-0676736C-0737-4CE8-A5F1-62C0C9AE6498 Q38289271-C5D76A42-5BF3-4A20-A203-9A94624C9543 Q38494470-BDB03272-20B1-4626-8C06-93DA1EA5B1BD Q38991978-8169E9B2-C6DA-4326-A114-5BF73C0AFB16 Q39028890-D12F3F55-94D4-4121-B4BB-BEEC27C8A399 Q39129968-3BABE18A-CACE-4138-8AD5-4E7D059ED6B4 Q39154733-D88A9125-3A51-4BBF-8E8F-AB9FD508CEFF Q41608170-15216F5F-BBFE-4B08-A904-1F4CC4B403DE

P2860

Development and optimization of nanosomal formulations for siRNA delivery to the liver

http://www.wikidata.org/entity/Q35816825

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@ast

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@en

type

label

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@ast

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@en

prefLabel

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@ast

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@en

P1433

Q35816825-68DBA655-8DFA-43D2-9916-9A3DA8C407BC

P1476

Q35816825-AB07BDA3-455B-40B3-99BB-A60C5AA98973

P2093

Q35816825-1FDEA6C7-DDF3-42F6-88DE-E5E8B62AC756

Q35816825-5C51528C-50ED-4435-BE2D-FFE735E69517

Q35816825-66277BDD-3E80-4628-88A3-7C40056C6736

Q35816825-7EE7876F-E27B-4577-B6FE-43D626E4814F

Q35816825-9B5728DE-E8F6-4403-AD1A-6DC68B8101CA

Q35816825-DA89E586-7D17-42B1-9C09-D658E0808788

P2860

Q35816825-06F305DA-AE83-4BC5-8D0D-3BD973779D05

Q35816825-14FCD7A8-AE1A-4426-810A-C3BB6C4C9C3F

Q35816825-1890A56A-85A9-4C23-B718-C2DA6460B1CF

Q35816825-26E30D5E-DEDD-47D9-96D9-47CF7E58368F

Q35816825-2D9821D2-79A0-4791-A35B-FE549EC48EF1

Q35816825-2FF58CF0-4692-49F3-AF05-3CDD3E5A88B9

Q35816825-30A41AAE-8501-4ED2-BD2B-A120AD26B1E1

Q35816825-38146CF4-EB1F-412D-9421-B074256DD50A

Q35816825-39A225A1-ADE0-4F0E-87C9-B3D7CA7E7497

Q35816825-3D0D9B8E-B6E3-4BA6-BF5C-C26FFBFDC57F

P304

Q35816825-A0278CAC-02D0-4DF5-89C9-86AB90E88ADB

P31

Q35816825-629F32B9-FF8E-4814-9117-686EDD9FB092

P356

Q35816825-B0443CF2-6924-4DD0-A0DB-19DF3F00D750

P407

Q35816825-8876FC2D-43B6-4DF7-9C2D-A1E44A1278E1

P433

Q35816825-1BF65E32-FA1C-41DF-ACCC-448B092B6CB2

P478

Q35816825-6C794310-5F0A-4931-9467-54F6BF1D4DBE

P577

Q35816825-4D4EADAB-C8AB-4FE6-896A-EB3F3BBDB096

P5875

Q35816825-C3A899F5-DC79-4540-9A95-D4C40E5CB5BA

P698

Q35816825-CA0F5E25-D6C4-49BB-A979-54C49160CCCF

P932

Q35816825-C55774CF-D4A6-4C39-95B1-92A73C84DF4B

P356

J.EJPB.2011.10.023

P1433

European Journal of Pharmaceutics and Biopharmaceutics

P1476

Development and optimization of nanosomal formulations for siRNA delivery to the liver

@en

P2093

Anup K Kundu

http://www.w3.org/2001/XMLSchema#string

Partha K Chandra

http://www.w3.org/2001/XMLSchema#string

Sidhartha Hazari

http://www.w3.org/2001/XMLSchema#string

Srikanta Dash

http://www.w3.org/2001/XMLSchema#string

Tarun K Mandal

http://www.w3.org/2001/XMLSchema#string

Yashoda V Pramar

http://www.w3.org/2001/XMLSchema#string

P2860

Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review.

Combined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing

Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Strategies for silencing human disease using RNA interference

Particle size distribution in DMPC vesicles solutions undergoing different sonication times.

Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Cationic lipids enhance siRNA-mediated interferon response in mice.

Dicers at RISC; the mechanism of RNAi.

P304

257-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJPB.2011.10.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51830534

http://www.w3.org/2001/XMLSchema#string

P698

22119665

http://www.w3.org/2001/XMLSchema#string

P932

3298086

http://www.w3.org/2001/XMLSchema#string